Fig. 3

Expression pattern and diagnostic values of CEA, lncUEGC1 and lncUEGC2 in the validation set. a Serum CEA levels were detected in CAG (n = 18), stage I GC (n = 23), and stage II GC (n = 28) patients and in healthy controls (n = 60). b and c qPCR analysis of the relative plasma exosomal lncUEGC1 (b) and lncUEGC2 (c) levels in CAG (n = 18), stage I GC (n = 23), and stage II GC (n = 28) patients and in healthy controls (n = 60). d ROC curve of serum CEA levels, relative plasma exosomal lncUEGC1 and lncUEGC2 levels in stage I and II GC patients (n = 51) and healthy controls (n = 60). e ROC curve of serum CEA levels and relative plasma exosomal lncUEGC1 and lncUEGC2 levels in stage I GC patients (n = 23) and healthy controls (n = 60). f ROC curve of serum CEA levels and relative plasma exosomal lncUEGC1 and lncUEGC2 levels in stage I GC patients (n = 23) and CAG patients (n = 18). Differences with P < 0.05 were considered statistically significant. NS, not significant; **P < 0.01; ***P < 0.001; ****P < 0.0001